New study explores Longidaza-supplemented BPH combination therapy

A combination therapy with Longidaza^® and alpha blockers has demonstrated significant improvement in treatment outcomes for benign prostatic hyperplasia (BPH). These data were revealed in ADAM, a multicenter randomized prospective open-label study^[1] presented at the 24th Congress of the Russian Society of Urology in Ekaterinburg in September 2024^[2].

BPH, also known as prostate adenoma, typically occurs in men over 45 years of age, but can also begin as early as 40 years of age^[3]. Its main symptoms include urination issues, feeling of incomplete bladder emptying and incontinence. All these problems significantly reduce quality of life.

D.Yu. Pushkar, Dr. habil. med., Professor, Academician of the Russian Academy of Sciences, Chief Urologist of the Ministry of Health of Russia, explains that a significant part of male population all over the world and Russia in particular experience BPH symptoms.

Depending on how serious the disease is, patients with such symptoms can be treated with either medication or surgery.

Alpha blockers are used most commonly as a medication to treat LUTS (lower urinary tract symptoms) in men. A novel pathogenetic method to solve this issue is therapy supplemented by enzyme products added to enhance its therapeutic effect.

ADAM, a study run in several medical centers across Russia, demonstrated that when Longidaza (bovhyaluronidase azoximer) was used in combination with alpha blockers, it significantly alleviated the condition of BPH patients compared to monotherapy. Improvements were observed as early as day 26 of therapy and persisted long-term.

Other studies reinforce the positive results Longidaza^® has in urological practice. For example, an observational randomized study exploring the efficacy and safety of Longidaza^® when used to treat patients with both LUTS and prostate adenoma revealed more pronounced positive changes in terms of the average score on the IPSS (International Prostate Symptom Score) and QoL (urination-associated quality of life) scales and the average Qmax (maximum urine flow rate) according to the uroflowmetry results. Patients randomized in the group treated with Longidaza^® as part of combination therapy noticed lower prostate volumes^[4].

In addition, when Longidaza is used after surgical treatment for prostate adenoma, this significantly reduces the risk of complications and promotes faster recovery^[5].